Anti-Müllerian Hormone (AMH) as a quantitative and qualitative marker of euploid blastocysts.
Is AMH an effective tool to predict the percentage of euploid embryos and blastocyst formation irrespective of the age of the patient?
Higher AMH levels are associated with a higher rate of euploid embryos and increased blastocyst formation on day 5.
What is known already?
AMH is an established marker of the ovarian reserve and it is strongly correlated with female age.
However, it has been suggested that AMH is not only a quantitative but also a qualitative biomarker of oocyte/embryo competence and it has been demonstrated that high AMH levels, e.g. due to the Polycystic Ovary Syndrome, are at increased risk of poor blastocyst development. Reduced ovarian reserve might be per se associated with decreased oocyte developmental competence leading to increased aneuploidy rates in embryos independent of the age of the patient.